Searching for treatments for non-G12C-KRAS mutant cancers

KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS(G12C) mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Christina, Banerji, Udai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405631/
https://www.ncbi.nlm.nih.gov/pubmed/33859342
http://dx.doi.org/10.1038/s41416-021-01357-2
_version_ 1783746367141707776
author Guo, Christina
Banerji, Udai
author_facet Guo, Christina
Banerji, Udai
author_sort Guo, Christina
collection PubMed
description KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS(G12C) mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers.
format Online
Article
Text
id pubmed-8405631
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84056312021-09-16 Searching for treatments for non-G12C-KRAS mutant cancers Guo, Christina Banerji, Udai Br J Cancer Comment KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS(G12C) mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, a dual RAF–MEK inhibitor, has reported early single agent activity in non-G12C mutated KRAS driven cancers. Nature Publishing Group UK 2021-04-15 2021-08-31 /pmc/articles/PMC8405631/ /pubmed/33859342 http://dx.doi.org/10.1038/s41416-021-01357-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Guo, Christina
Banerji, Udai
Searching for treatments for non-G12C-KRAS mutant cancers
title Searching for treatments for non-G12C-KRAS mutant cancers
title_full Searching for treatments for non-G12C-KRAS mutant cancers
title_fullStr Searching for treatments for non-G12C-KRAS mutant cancers
title_full_unstemmed Searching for treatments for non-G12C-KRAS mutant cancers
title_short Searching for treatments for non-G12C-KRAS mutant cancers
title_sort searching for treatments for non-g12c-kras mutant cancers
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405631/
https://www.ncbi.nlm.nih.gov/pubmed/33859342
http://dx.doi.org/10.1038/s41416-021-01357-2
work_keys_str_mv AT guochristina searchingfortreatmentsfornong12ckrasmutantcancers
AT banerjiudai searchingfortreatmentsfornong12ckrasmutantcancers

Ejemplares similares